Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Support
This activity is supported by educational grants from Genmab US, Inc., Incyte Corporation, Janssen, and Pharmacyclics, an AbbVie Company.
Medical Crossfire®: How Are We Integrating New Treatment Strategies Into the Care of Our B-Cell Lymphoma Patients?
Release Date: September 22, 2021
Expiration Date: September 22, 2022
Activity Overview
This online, on-demand, virtual symposium brings together renowned experts in lymphoma to discuss the latest treatment strategies for patients with follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL). This program also features the dynamic Medical Crossfire® format, which gives participants the opportunity to hear multiple perspectives on addressing clinical challenges in the management of patients with FL, MZL, and MCL.
This educational activity is an archive of the live virtual webcast held on September 10, 2021.
Acknowledgement of Commercial Support
This activity is supported by educational grants from Genmab US, Inc., Incyte Corporation, Janssen, and Pharmacyclics, an AbbVie Company.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
These activities are intended for medical oncologists, hematologists, and other oncology health care professionals interested in the latest advances in the treatment of patients with non-Hodgkin lymphoma. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with non-Hodgkin lymphoma are also invited to attend.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Explain diagnostic and prognostic biomarkers underlying treatment decisions in MZL, FL, and MCL
- Evaluate safety and efficacy profiles for evolving therapeutic options that have been investigated for the treatment of MZL, FL, and MCL
- Integrate practice-changing data and evidence-based recommendations into personalized treatment plans for patients with MZL, FL, and MCL, including strategies to monitor and mitigate therapy-related adverse events
- Assess the recent clinical trial results and ongoing trials evaluating novel agents, alone or in combination, for patients with MZL, FL, and MCL
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
Faculty
Associate Professor of Medicine
Harvard Medical School
Chief, Division of Lymphoma
Harold and Virginia Lash Endowed Chair in Lymphoma Research
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Grant research support: Merck & Co., Inc.; Bristol Myers Squibb; Affimed GmbH; Adaptive Biotechnologies; F. Hoffmann-La Roche AG; Genentech, Inc.; IGM Biosciences; Kite Pharma; Consultant: Merck & Co., Inc.; Bristol Myers Squibb; Pfizer; Affimed GmbH; Adaptive Biotechnologies; Infinity Pharmaceuticals; ADC Therapeutics; Celgene Corporation; MorphoSys AG; Daiichi Sankyo Company Ltd; Miltenyi Biotec Inc.; Tessa Therapeutics; GenMab US, Inc.; C4 Therapeutics; Enterome; Regeneron Pharmaceuticals, Inc.; Epizyme, Inc.; AstraZeneca; Genentech, Inc.; Other: Honoraria: Bristol Myers Squibb, Merck & Co., Inc.
Associate Professor, Department of Lymphoma/Myeloma
Director, Lymphoma Outcomes Database
Section Chief, Indolent Lymphoma and New Drug Development
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant research support: Bristol Myers Squibb/Celgene; Caribou Biosciences; Epizyme, Inc.; Genentech, Inc.; IGM Biosciences; Janssen; Merck & Co., Inc.; Novartis; TG Therapeutics; Takeda Oncology; Consultant: ADC Therapeutics; Bayer; Bristol Myers Squibb/Celgene; Genentech, Inc.; Gilead Sciences/Kite Pharma; Janssen; MorphoSys AG; Novartis; TG Therapeutics; Takeda Oncology.
Associate Professor, Department of Lymphoma/Myeloma
Director, Lymphoma Clinical Research
Section Chief, Aggressive Lymphoma
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant research support: Kite Pharma; Novartis; Bristol Myers Squibb; Janssen; Genentech, Inc.; Unum Therapeutics; Forty Seven, Inc.; AstraZeneca; MorphoSys AG; Curis, Inc.; Consultant: Kite Pharma; Novartis; Bristol Myers Squibb; Janssen; Genentech, Inc.; AstraZeneca; MorphoSys AG; Curis, Inc.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
